Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

NCT04064359 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: OBT076, a CD205-directed antibody-drug conjugate

Sponsor

Oxford BioTherapeutics Ltd